Capitolis Advisors LLC Abb Vie Inc. Transaction History

Capitolis Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$131.98 - $163.75 $24.5 Million - $30.3 Million	-185,318 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$107.43 - $135.93 $2.4 Million - $3.04 Million	22,345 Added 13.71%	185,318 $25.1 Million
Q2 2021 Aug 11, 2021	SELL	$105.21 - $117.21 $18.9 Million - $21.1 Million	-179,738 Reduced 52.45%	162,973 $18.4 Million
Q1 2021 May 13, 2021	BUY	$102.3 - $112.62 $9.81 Million - $10.8 Million	95,914 Added 38.86%	342,711 $37.1 Million
Q4 2020 May 07, 2021	BUY	$80.49 - $108.67 $19.9 Million - $26.8 Million	246,797 New	246,797 $26.4 Million

3,846

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $295B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Capitolis Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Capitolis Advisors LLC with notifications on news.